Theralase Technologies (CVE:TLT) Shares Down 15.8% – Time to Sell?

Theralase Technologies Inc. (CVE:TLT) shares dropped 15.8% during mid-day trading on Tuesday . The company traded as low as C$0.32 and last traded at C$0.32. Approximately 116,882 shares traded hands during trading, an increase of 1% from the average daily volume of 115,945 shares. The stock had previously closed at C$0.38.

Theralase Technologies Stock Down 12.3 %

The company has a current ratio of 1.21, a quick ratio of 3.40 and a debt-to-equity ratio of 20.58. The company has a 50-day simple moving average of C$0.19 and a 200 day simple moving average of C$0.18. The company has a market cap of C$78.57 million, a P/E ratio of -16.00 and a beta of 1.36.

Theralase Technologies (CVE:TLT) last posted its quarterly earnings results on Monday, August 12th. The company reported C($0.01) EPS for the quarter. The firm had revenue of C$0.10 million for the quarter. On average, equities analysts anticipate that Theralase Technologies Inc. will post -0.05 EPS for the current year.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.